 |
 |

Decreased Somal Size of Deep Layer 3 Pyramidal Neurons in the Prefrontal Cortex of Subjects With Schizophrenia
Joseph N. Pierri, MS, MD;
Christine L. E. Volk, BS;
Sungyoung Auh, MS;
Allan Sampson, PhD;
David A. Lewis, MD
Arch Gen Psychiatry. 2001;58:466-473.
ABSTRACT
Background Schizophrenia is associated with deficits in working memory, a cognitive
function that depends on the connections of the prefrontal cortex (PFC) with
the thalamus and other cortical regions. Pyramidal neurons in PFC deep layer
3 play a central role in both thalamocortical and corticocortical circuitry.
Given that somal size tends to be associated with both the dendritic and axonal
architecture of a neuron, abnormalities in these circuits in schizophrenia
may be associated with a change in the somal size of deep layer 3 pyramidal
neurons.
Methods We used design-based stereology to estimate the somal volume of pyramidal
neurons in deep layer 3 of PFC area 9 in 28 subjects with schizophrenia, each
of whom was matched to 1 normal comparison subject for sex, age, and postmortem
interval.
Results The geometric mean of the somal volume estimates in the subjects with
schizophrenia was significantly (P =.02) decreased
by 9.2%. This decrease was associated with a shift in the distribution of
somal volumes toward smaller sizes. Neither antipsychotic medication treatment
history nor duration of illness was associated with somal size.
Conclusions These findings independently replicate previous reports of decreased
somal size in the PFC in schizophrenia. The reduction in size of deep layer
3 pyramidal neurons is consistent with abnormalities in thalamocortical and
corticocortical circuitry, suggesting that disruption of these circuits may
contribute to cognitive abnormalities in schizophrenia.
INTRODUCTION
WORKING memory is impaired in persons with schizophrenia,1, 2
and these abnormalities are associated with altered function of the dorsal
prefrontal cortex (dPFC).3, 4 In
addition, studies in nonhuman primates indicate that working memory requires
the integrity of dPFC connections with other cortical regions and the thalamus.5, 6
Recent studies have reported alterations in layer 3 of the dPFC in schizophrenia.
Rajkowska et al7 described a decrease in the
mean somal size of all layer 3 neurons and a decrease in the density of the
largest neurons in deep layer 3. The authors interpreted this finding to suggest
that large pyramidal neurons in deep layer 3 may be most affected in schizophrenia.
Interestingly, the density of dendritic spines, a marker of the number of
excitatory inputs to pyramidal neurons,8 has
been found to be significantly decreased on layer 3 pyramidal neurons in subjects
with schizophrenia,9 and this abnormality was
reported to be most prominent on pyramidal neurons in deep layer 3 of the
dPFC.10
Pyramidal neurons in deep layer 3 of the dPFC play a key role in both
corticocortical and thalamocortical circuitry. The principal axons of these
neurons project to cortical association areas, such as the superior temporal
gyrus and the inferior parietal cortex.11, 12, 13
In addition, intrinsic axon collaterals of layer 3 pyramidal neurons furnish
wide-spreading, horizontal excitatory connections within the dPFC.14, 15, 16, 17 Furthermore,
deep layer 3 pyramidal neurons are located in the termination zone of axon
projections from the mediodorsal thalamic nucleus,18
and thus likely receive excitatory input from this nucleus.
Because neuronal size is correlated with the extent of a neuron's dendritic19, 20 and axonal arbor,21, 22
a decrease in somal size may reflect decreased afferent and/or efferent connectivity
of these neurons in schizophrenia. Consequently, we tested the hypothesis
that the somal size of deep layer 3 pyramidal neurons in dPFC area 9 is decreased
in individuals with schizophrenia.
SUBJECTS AND METHODS
SUBJECTS
With the consent of the next of kin and the approval of the Health Sciences
Institutional Review Board of the University of Pittsburgh, we obtained brain
specimens from 56 subjects during autopsies conducted at the Allegheny County
(Pittsburgh) Coroner's Office (Table 1).
Neuropathological examinations revealed no abnormalities in any of the subjects
except for the following: thioflavin-S staining revealed a few neuritic plaques
in 3 normal comparison subjects (pairs 3, 4, and 24) and in 1 subject with
schizophrenia (pair 6), but they did not meet either clinical or neuropathological
criteria for Alzheimer disease.23 Two subjects
with schizophrenia died of cerebrovascular events (pair 6, left parietal subdural
hematoma; pair 12, intracerebral hemorrhage in the right temporal lobe), but
the left dPFC was not affected. An independent panel of experienced clinicians
made consensus DSM-III-R diagnoses as described previously.24
|
|
|
|
Subjects Examined in This Study*
|
|
|
Twenty-eight subjects diagnosed as having schizophrenia or schizoaffective
disorder (Table 1) were each matched
to 1 comparison subject for sex, age, and postmortem interval (PMI). Individual
pairs were completely matched for sex, and the mean ± SD differences
in age and PMI within pairs were 3.8 ± 3.0 years and 2.6 ± 2.1
hours, respectively. Mean values for these variables (Table 1) and percentage of out-of-hospital deaths (comparison group,
96.4%; schizophrenia group, 89.3%) did not differ between the 2 groups. For
subjects with schizophrenia, the mean ± SD age of onset was 27.3 ±
9.0 years and the duration of illness was 25.8 ± 11.8 years. Five of
these subjects died by suicide, and 13 had a history of an alcohol or substance
userelated disorder; these diagnoses were current at the time of death
for 8 subjects. Toxicology examinations were positive for plasma alcohol in
3 subjects with schizophrenia (pairs 4 [0.13%], 7 [0.12%], and 27 [0.09%])
and in 2 comparison subjects (pairs 11 [0.03%] and 20 [0.01%]). Six subjects
with schizophrenia had not been taking antipsychotic medication for at least
1 month prior to death, and 1 (pair 16) never received treatment (Table 1).
TISSUE PREPARATION
The left hemisphere of each brain was cut into 1.0-cm-thick coronal
blocks, immersed in ice-cold 4% paraformaldehyde in phosphate buffer for 48
hours, washed in a graded series of sucrose solutions, and stored in an antifreeze
solution at -30°C. Tissue storage time did not differ between the
subject groups (Table 1). From
blocks located 2 to 4 cm from the frontal pole, 40-µm coronal sections
were cut on a cryostat. Every tenth section was mounted on slides and stained
for Nissl substance with thionin. From a series of sections determined by
cytoarchitectonic criteria25, 26
to contain dPFC area 9 (Figure 1),
we selected 4 sections, each separated by 400 µm, for somal size estimation.
These slides were placed in random order and coded for blinded quantification.
|
|
|
|
Figure 1. Brightfield photomicrograph of
Nissl-stained neurons in prefrontal cortex area 9. Note that pyramidal neurons
in deep layer 3 are oriented parallel to the plane of section and perpendicular
to the pial surface, consistent with the concept of a local vertical design.
The 6 cortical layers and white matter (WM) are identified. The bracket indicates
the lower one third of layer 3, where pyramidal neurons were sampled and measured.
Scale bar = 300 µm.
|
|
|
MEASUREMENT OF SOMAL SIZE
Quantification was performed without knowledge of diagnosis by one rater
(C.L.E.V.). Using a Zeiss Axioplan microscope equipped with Stereo Investigator
software27 and a Microvid Monitor (MicroBrightField,
Inc, Colchester, Vt), area 9 was identified at low magnification (x50),
the border between layers 3 and 4 was located (Figure 1), and a contour outlining the lower third (determined by
measuring the width of layer 3) of layer 3 was drawn (Figure 2A). The mean ± SD contour area per section was 1.93
± 0.33 x 106 µm2 for the comparison
subjects and 1.85 ± 0.36 x 106 µm2
for the subjects with schizophrenia. Magnification was then changed to x1000,
using a 1.4 numerical aperture, x100, oil immersion objective, for cell
measurements. To randomly sample cells, we used the optical fractionator28 probe of the Stereo Investigator software, which
systematically and randomly placed 18 to 22 sampling boxes throughout the
region of interest (Figure 2B).
Each box was 110 x 75 x 8 µm in the x, y, and z directions,
respectively (Figure 2C). At each
sampling site, sampling was begun 2 µm below the section surface. Sections
had a mean ± SD thickness of 14.0 ± 1.0 µm for both the
comparison and schizophrenia groups. To estimate somal volume, we used the
nucleator probe29 of the Stereo Investigator
software, in a local vertical section design.30
That is, we only measured neurons in regions of area 9 where the long axis
of the neurons was judged to be parallel to the plane of the section and perpendicular
to the pial surface (Figure 1 and Figure 2 D). This design assumes that pyramidal
neurons in deep layer 3 are isotropically oriented about the vertical axis
of the tissue.
|
|
|
|
Figure 2. Schematic of the sampling and
somal volume estimation procedure. Panel A shows a camera lucida drawing of
the superior frontal gyrus in area 9. The gray area indicates the approximate
medial and lateral boundaries of area 9. Within this area, where pyramidal
neurons met criteria for a local vertical design, a contour was drawn outlining
the lower one third of layer 3. B, A sampling grid was randomly superimposed
over this area to designate sampling sites. C, At each sampling site, a 3-dimensional
sampling frame was used to identify neurons for measurement according to unbiased
inclusion and exclusion rules (broken and solid lines indicate inclusion and
exclusion boundaries, respectively). Each neuron was measured at a final magnification
of x1000 using the nucleator principle (D), which involves identifying
the nucleolus of each pyramidal neuron by clicking on it with the cursor,
and marking (arrow) where each of a set of 5 equidistant (separated by 72°)
rays, which randomly overlay the neuron, intersect the boundary of the soma.
The photomicrograph depicts a pyramidal neuron undergoing this procedure.
|
|
|
For each neuron, the nucleolus was used as the cell's uniquely associated
reference point. To estimate somal size, the operator clicked on the nucleolus,
which brought up a set of 5 two-dimensional isotropic random rays (Figure 2D). The operator clicked on each
ray where it intersected the boundaries of the soma. The formula used to calculate
volume was as follows: volume = 4/3 În3, where
Î equals the mean segment length from the nucleolus to the cell boundary,
and n equals the number of segments, in this case, 5.
Only cells within the 3-dimensional sampling box meeting the following
criteria for pyramidal neurons were measured: (1) a clearly identifiable nucleolus,
(2) an abundance of Nissl-stained cytoplasm, (3) a clearly visible vertical
apical dendrite, and (4) a triangular shape. The mean ± SD number of
neurons measured for each subject did not differ between the control subjects
(265 ± 44) and the subjects with schizophrenia (261 ± 45). The
mean ± SD coefficients of error for average somal volume were 4.5%
± 0.6% for comparison subjects and 4.6% ± 0.6% for subjects
with schizophrenia.
STATISTICAL METHODS
Individual and group somal volume distributions for all measured neurons
in each diagnostic group showed a skew toward the larger somal sizes (Figure 3A). To normalize the data, all single
neuron volume estimates were transformed using a natural log function31 (Figure 3B).
For each subject, estimates of somal volume were averaged over the neurons
within each of the 4 sections. These averages were treated as 4 correlated
observations. Exploratory regression analyses done to assess the effects of
sex, age, PMI, and tissue storage time on somal volume indicated a potential
effect of PMI on somal volume, which was confirmed in formal modeling. To
examine a main effect of diagnosis, a multivariate analysis of covariance
(MANCOVA) model assuming a compound symmetric covariance structure32 was used. To test for a main effect of diagnosis,
pair was used as a blocking factor and tissue storage time as a covariate.
In this model, the pair factor accounts for the effect of PMI, as subjects
were matched, on a pairwise basis, for sex, age, and PMI. This model was validated
by using the MANCOVA procedure to assess both diagnosis and pair factors,
with tissue storage time and PMI as covariates, as well as by including all
pairing factors (age, sex, and PMI) and tissue storage time as covariates
in the MANCOVA model. As all 3 models yielded similar results, only the results
of the primary model are reported.
|
|
|
|
Figure 3. Percentage of neurons across somal
size bins for both the comparison subjects and the subjects with schizophrenia,
both before (A) and after (B) the natural log transformation of individual
somal volume estimates.
|
|
|
Analyses were implemented in SAS PROC Mixed.33
All statistical tests were performed on the log-transformed estimates of somal
volume, and summary descriptions of somal volume were obtained by back transformation
of the summary statistics of log-transformed somal volume. Back transformation
yields geometric means that are estimates of median somal volume.34 The distributions of somal size for the 2 diagnostic
groups are described using 25% and 75% quartiles, obtained through back transformation.
To examine changes in the distribution of somal volumes between diagnostic
groups, arbitrary cutoff values were used to create 4 somal size categories.
The mean percentages of neurons for each subject in the 3 smallest size categories
were compared across diagnostic groups using a MANCOVA model that assumed
an intraclass covariance matrix with pair as a blocking variable.
Within the schizophrenia group, we also used an intraclass covariance
matrix MANCOVA model to evaluate the effects of age of onset and duration
of illness on somal volume. Because age at the time of death was correlated
with both age of onset and duration of illness, it was included as a covariate
for these analyses. In exploratory analyses, we used an analysis of covariance
model with PMI as the covariate to evaluate the effects of suicide, substance
abuse history, and medication status at the time of death on differences in
log-transformed somal volumes between subjects with schizophrenia and comparison
subjects.
All statistical tests were conducted with = .05.
RESULTS
The primary MANCOVA model revealed a significant (F1,26 =
5.76; P = .02) 9.2% decrease in the geometric mean
of the somal volume of the subjects with schizophrenia (2084.3 µm3; 25% quartile, 1795.4 µm3; 75% quartile, 2383.2 µm3) compared with that of the matched comparison subjects (2295.7 µm3; 25% quartile, 1980.3 µm3; 75% quartile, 2600.3 µm3) (Figure 4). In 18 of 28
of the pairs, the subject with schizophrenia had a geometric mean somal volume
estimate that was lower than the matched comparison subject. Somal volume
was decreased in subjects with "pure" schizophrenia and in those with schizoaffective
disorder relative to their matched controls, although in separate exploratory
analyses neither difference was significant (F1,39 = 1.81; P<.19 and F1,11 = 3.55; P<.09, respectively).
|
|
|
|
Figure 4. Geometric means of the somal volumes
for the comparison subjects and the subjects with schizophrenia. Cross bars
indicate the geometric means for each diagnostic group.
|
|
|
The distributions of somal sizes (Figure
5) revealed that the subjects with schizophrenia had higher percentages
of neurons in the smaller cell size categories and lower percentages in the
larger 2 categories compared with the comparison subjects. The MANCOVA model
used to compare the cell category percentages between comparison subjects
and subjects with schizophrenia showed a significant diagnosis x somal
size category interaction (F2,108 = 4.9; P
= .009). To determine the differences in the distributions of somal size that
accounted for this interaction, we used paired t
tests, adjusted to have a simultaneous .05 significance level, to examine
the differences in changes in percentages of neurons across size categories
for the 2 diagnostic groups. This analysis showed that between the "1001-3000
µm3" and the "3001-5000 µm3" categories,
the subjects with schizophrenia exhibited a decrease in the percentage of
neurons, whereas the comparison subjects exhibited an increase. The difference
in these changes was significant (t108
= 2.8, simultaneous P = .02), and consistent with
a shift in the somal size distribution toward smaller cell sizes for the subjects
with schizophrenia.
|
|
|
|
Figure 5. Mean ± SD percentages of
deep layer 3 pyramidal neurons in arbitrarily defined somal volume categories
for the comparison subjects and the subjects with schizophrenia. Note that
the subjects with schizophrenia appear to have fewer large neurons and more
small neurons than the comparison subjects.
|
|
|
The mean ± SD width of layer 3 did not differ (F1,27
= 0.18; P>.68) between the comparison subjects (993.1
± 81.7 µm) and the subjects with schizophrenia (1003.7 ±
86.3 µm).
We found no significant associations between age of onset (F1,24 = 0.11; P = .75) or duration of illness (F1,24 = 0.09; P = .77) and somal size. In addition,
differences in log-transformed somal volumes between the subjects with schizophrenia
and their matched comparison controls did not vary (F1,25<0.10; P>.75) as a function of sex, suicide, or history of alcohol
and/or substance abuse (Figure 6A-C).
Finally, differences in somal size between subjects with schizophrenia and
the their matched controls were not affected by antipsychotic medication treatment
status at the time of death (F1,25 = 0.25; P = .62) (Figure 6D).
|
|
|
|
Figure 6. Mean ± SD of the geometric
means of somal volume estimates for the comparison subjects and the subjects
with schizophrenia grouped by sex (A) (female, n = 10; male, n = 18), cause
of death (B) (suicide, n = 5; other, n = 23), history of substance abuse (C)
(no, n = 15; yes, n = 13), and antipsychotic medications at the time of death
(D) (no, n = 7; yes, n = 21). Groupings were based on the status of the subjects
with schizophrenia for each of these variables.
|
|
|
COMMENT
In this study, subjects with schizophrenia showed a significant 9.2%
decrease in the somal volume of pyramidal neurons in deep layer 3 of PFC area
9, with a shift in the somal volume distribution toward smaller cell sizes.
Decreased somal size was not related to duration or age of onset of illness,
sex, death by suicide, history of alcohol or substance use, or antipsychotic
medication treatment at the time of death.
The strengths of this study include (1) the sample size; (2) the use
of an optical fractionator design, which enabled systematic random sampling
within area 9; and (3) the use of the nucleator, which permitted estimates
of somal volume.29 However, several potential
confounds must be considered in interpreting the pathophysiological significance
of our observations.
First, the stereological design of this study has limitations. Although
a relatively large volume of area 9 was sampled, we did not sample throughout
the region of interest. Consequently, caution must be used when generalizing
findings from our sampling scheme to all deep layer 3 pyramidal neurons in
area 9. Also, our method for estimating somal volume did not take into account
the possibility that alterations in the shape or orientation of pyramidal
neurons in schizophrenia could lead to underestimates or overestimates of
somal volume. However, despite these caveats, the fact that a decrease in
somal size of deep layer 3 pyramidal neurons has been reported by another
independent group,7 using a different sampling
scheme and estimator of cell size, strongly suggests that decreased somal
size of deep layer 3 pyramidal neurons in schizophrenia is unlikely to be
the result of biased measurement methods.
Second, terminal conditions associated with changes in brain volume,
such as prolonged hypoxemia, could result in altered somal size. However,
in this study, 92% of the subjects died suddenly, out of hospital, consistent
with a limited agonal state.
Third, neuronal size may change as a function of PMI,19, 35
as was observed in this study. However, subject pairs were closely matched
for PMI, and inclusion of PMI as a covariate revealed that subjects with schizophrenia
still showed a significant decrease in somal volume.
Fourth, the duration of brain tissue fixation represents a potential
confound since tissue volume shrinks as much as 14% after prolonged fixation.36 In the present study, each specimen was processed
following a standard protocol, with a brief fixation time (48 hours), that
was identical for both diagnostic groups.
Finally, long-term exposure to antipsychotic medications might confound
estimates of somal volume, as dose of antipsychotic medication has been found
to be negatively associated with frontal lobe volume in schizophrenia.37 In the present study, the somal volumes of subjects
with schizophrenia who were not taking antipsychotic medications at the time
of death did not differ from subjects who were (Figure 6D). Moreover, the somal volume of the subject with schizophrenia
who had never been treated with antipsychotic medications was less than that
of the matched comparison subject.
Decreased somal size is consistent with and possibly related to other
reported abnormalities of dPFC layer 3 pyramidal neurons in schizophrenia,
such as decreased dendritic spine density.9, 10
Specifically, a decrease in the density of basilar dendritic spines on deep
layer 3 pyramidal neurons was associated with a decrease in the total length
of these dendrites, as well as a nonsignificant decrease in somal size.10
Similar to previous studies of PFC pyramidal neurons,19, 20
we also found no relationship between somal size and age at time of death
in our subjects, confirming that somal size is stable across adulthood. Furthermore,
somal volume in schizophrenia was not related to age of onset or duration
of illness, suggesting that reductions in somal volume may not progress with
time, and that the events leading to decreased somal size may have occurred
during development before illness onset or during a limited progressive phase
of the illness.38
Alterations in deep layer 3 pyramidal neurons may be related to changes
in chandelier cells, a specific subset of cortical inhibitory neurons. Chandelier
neuron axon terminals (termed "cartridges") synapse on pyramidal neuron axon
initial segments, providing powerful regulation of pyramidal neuron output.39 In the dPFC, subjects with schizophrenia exhibit
a decrease in the density of cartridges immunoreactive for the -aminobutyric
acid transporter (GAT-1)40, 41;
interestingly, this decrease appeared to be greatest in deep layers 3 and
4 of the same subjects studied herein.41
Our findings also suggest that a reduction in somal volume may contribute
to the subtle reductions in dPFC volume found in neuroimaging studies of schizophrenia.42, 43, 44, 45, 46, 47
In addition, our findings may account for the reports of decreased concentrations
of dPFC N-acetylaspartate48, 49, 50, 51
in schizophrenia, since pyramidal cells make up the majority of neurons in
the cortex,8 and since the concentration of N-acetylaspartate may be greatest in these neurons.52 Interestingly, in subjects with schizophrenia, N-acetylaspartate levels in the dPFC were positively correlated
with changes in cortical activation, as measured by regional blood flow, in
the prefrontal, temporal, and parietal association cortices during performance
of a working memory task.53 This relationship,
found only for the dPFC, suggests that activation of the working memory network
may be determined by the integrity of corticocortically projecting dPFC pyramidal
neurons.13, 53
Understanding the pathophysiological significance of a decrease in the
somal size of pyramidal neurons in deep layer 3 in persons with schizophrenia
depends on whether this abnormality reflects a defect intrinsic to deep layer
3 pyramidal neurons or an extrinsic defect in the inputs they receive. An
intrinsic defect may be manifest in a decrease in the capacity of these neurons
to form and maintain appropriate afferent and efferent connections. For example,
in certain neuronal populations, somal size correlates with the extent of
a neuron's dendritic19, 20 and
axonal arbor.21, 22 If these correlations
apply to the findings of the present study, we would expect evidence for decreases
in these components of pyramidal neuron architecture. Indeed, this possibility
is suggested by reported abnormalities in spine density and total dendritic
length. Interestingly, for 12 subjects with schizophrenia in the present study,
who were also examined in a previous study of spine density,10
average total dendritic length, measured in Golgi-stained deep layer 3 pyramidal
neurons, and average somal volumes, estimated herein, are significantly correlated
(r = 0.64, P = .02). In
contrast to measures of a neuron's dendritic arbor, the axonal arbor of a
neuron is much more difficult to measure in the postmortem state. However,
given that layer 3 pyramidal neurons participate in reciprocal short- and
long-range circuits intrinsic to the dPFC,16
a proportion of the decrease in pyramidal neuron spine density in schizophrenia
may be due to a decrease in axonal arbor.
On the other hand, a decrease in somal size could result from a loss
of input from other brain areas, such as the thalamus. Recent studies54, 55, 56, 57 of
the mediodorsal thalamic nucleus, which projects to the dPFC, have reported
a decrease in the number of neurons in subjects with schizophrenia. These
findings suggest that, in schizophrenia, deep layer 3 pyramidal neurons may
receive less excitatory drive from the thalamus, and consequently, they are
less active and hypotrophic. This possibility of "denervation atrophy" is
supported by experiments in which lesioning a subset of afferent inputs to
the PFC induced decreased somal size of layer 3 pyramidal neurons and decreased
performance on frontal lobe mediated tasks.58
Further studies are needed to determine whether abnormalities in dPFC
deep layer 3 pyramidal neurons in schizophrenia reflect an intrinsic defect
or are the result of altered inputs from other brain regions. Either possibility
would support the hypothesis that abnormal thalamocortical and corticocortical
circuitry underlie dPFC dysfunction in schizophrenia.
AUTHOR INFORMATION
Accepted for publication January 22, 2001.
This work was supported by US Public Health Service grants MH45156,
MH00519, MH18951, and MH60473 from the National Institute of Mental Health,
Rockville, Md, and a grant from the Stanley Foundation, Bethesda, Md.
We thank Mary Brady for assistance with the figures and Bente Pakkenberg,
MD, for advice on the experimental design.
From the Departments of Psychiatry (Drs Pierri and Lewis and Ms Volk),
Statistics (Ms Auh and Dr Sampson), and Neuroscience (Dr Lewis), University
of Pittsburgh, Pittsburgh, Pa.
Corresponding author and reprints: David A. Lewis, MD, University
of Pittsburgh, 3811 O'Hara St, W1650 BST, Pittsburgh PA 15213 (e-mail: Lewisda{at}msx.upmc.edu).
REFERENCES
1. Park S, Holzman PS. Schizophrenics show spatial working memory deficits. Arch Gen Psychiatry. 1992;49:975-982.
FREE FULL TEXT
2. Goldman-Rakic PS. Working memory dysfunction in schizophrenia. J Neuropsychiatry Clin Neurosci. 1994;6:348-357.
WEB OF SCIENCE
| PUBMED
3. Weinberger DR, Berman KF, Zec RF. Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia,
I: regional cerebral blood flow evidence. Arch Gen Psychiatry. 1986;43:114-124.
FREE FULL TEXT
4. Steinberg JL, Devous MD, Paulman RG. Wisconsin card sorting activated regional cerebral blood flow in first
break and chronic schizophrenic patients and normal controls. Schizophr Res. 1996;19:177-187.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
5. Fuster JM. The Prefrontal Cortex: Anatomy, Physiology, and Neuropsychology
of the Frontal Lobe. 3rd ed. Philadelphia, Pa: Lippincott-Raven; 1997.
6. Goldman-Rakic PS. Cellular basis of working memory. Neuron. 1995;14:477-485.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
7. Rajkowska G, Selemon LD, Goldman-Rakic PS. Neuronal and glial somal size in the prefrontal cortex. Arch Gen Psychiatry. 1998;55:215-224.
FREE FULL TEXT
8. DeFelipe J, Farinas I. The pyramidal neuron of the cerebral cortex: morphological and chemical
characteristics of the synaptic inputs. Prog Neurobiol. 1992;39:563-607.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
9. Garey LJ, Ong WY, Patel TS, Kanani M, Davis A, Mortimer AM, Barnes TRE, Hirsch SR. Reduced dendritic spine density on cerebral cortical pyramidal neurons
in schizophrenia. J Neurol Neurosurg Psychiatry. 1998;65:446-453.
FREE FULL TEXT
10. Glantz LA, Lewis DA. Decreased dendritic spine density on prefrontal cortical pyramidal
neurons in schizophrenia. Arch Gen Psychiatry. 2000;57:65-73.
FREE FULL TEXT
11. Goldman-Rakic PS. Topography of cognition: parallel distributed networks in primate association
cortex. Ann Rev Neurosci. 1988;11:137-156.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
12. Barbas H. Architecture and cortical connections of the prefrontal cortex in the
rhesus monkey. Adv Neurol. 1992;57:91-115.
PUBMED
13. Hof PR, Nimchinsky EA, Morrison JH. Neurochemical phenotype of corticocortical connections in the macaque
monkey: quantitative analysis of a subset of neurofilament protein-immunoreactive
projection neurons in frontal, parietal, temporal, and cingulate cortices. J Comp Neurol. 1995;362:109-133.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
14. Levitt JB, Lewis DA, Yoshioka T, Lund JS. Topography of pyramidal neuron intrinsic connections in macaque monkey
prefrontal cortex (areas 9 & 46). J Comp Neurol. 1993;338:360-376.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
15. Kritzer MF, Goldman-Rakic PS. Intrinsic circuit organization of the major layers and sublayers of
the dorsolateral prefrontal cortex in the rhesus monkey. J Comp Neurol. 1995;359:131-143.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
16. Pucak ML, Levitt JB, Lund JS, Lewis DA. Patterns of intrinsic and associational circuitry in monkey prefrontal
cortex. J Comp Neurol. 1996;376:614-630.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
17. Melchitzky DS, Sesack SR, Pucak ML, Lewis DA. Synaptic targets of pyramidal neurons providing intrinsic horizontal
connections in monkey prefrontal cortex. J Comp Neurol. 1998;390:211-224.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
18. Giguere M, Goldman-Rakic PS. Mediodorsal nucleus: areal, laminar, and tangential distribution of
afferents and efferents in the frontal lobe of rhesus monkeys. J Comp Neurol. 1988;277:195-213.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
19. Hayes TL, Lewis DA. Hemispheric differences in layer III pyramidal neurons of the anterior
language areas. Arch Neurol. 1993;50:501-505.
FREE FULL TEXT
20. Jacobs B, Driscoll L, Schall M. Life-span dendritic and spine changes in areas 10 and 18 of human cortex:
a quantitative Golgi study. J Comp Neurol. 1997;386:661-680.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
21. Lund JS, Lund RD, Hendrickson AE, Bunt AH, Fuchs AF. The origin of efferent pathways from the primary visual cortex, area
17, of the macaque monkey as shown by retrograde transport of horseradish
peroxidase. J Comp Neurol. 1975;164:287-304.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
22. Gilbert CD, Kelly JP. The projections of cells in different layers of the cat's visual cortex. J Comp Neurol. 1975;63:81-106.
23. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Bell G. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD),
part II: standardization of the neuropathological assessment of Alzheimer's
disease. Neurology. 1991;41:479-486.
FREE FULL TEXT
24. Glantz LA, Lewis DA. Reduction of synaptophysin immunoreactivity in the prefrontal cortex
of subjects with schizophrenia: regional and diagnostic specificity. Arch Gen Psychiatry. 1997;54:943-952.
FREE FULL TEXT
25. Rajkowska G, Goldman-Rakic PS. Cytoarchitectonic definition of prefrontal areas in the normal human
cortex, I: remapping of areas 9 and 46 using quantitative criteria. Cereb Cortex. 1995;5:307-322.
FREE FULL TEXT
26. Daviss SR, Lewis DA. Local circuit neurons of the prefrontal cortex in schizophrenia: selective
increase in the density of calbindin-immunoreactive neurons. Psychiatry Res. 1995;59:81-96.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
27. Stereo Investigator Version 3.0. Colchester, Vt: MicroBrightField Inc; 1998.
28. Gundersen HJG, Bagger P, Bendtsen TF, Evans SM, Korbo L, Marcussen N, Moller A, Nielsen K, Nyengaard JR, Pakkenberg B, Sorensen FB, Vesterby A, West MJ. The new stereological tools: dissector, fractionator, nucleator and
point sampled intercepts and their use in pathological research and diagnosis. Acta Pathol Microbiol Immunol Scand. 1988;96:857-881.
29. Gundersen HJG. The nucleator. J Microscopy. 1988;151:3-21.
WEB OF SCIENCE
| PUBMED
30. Howard CV, Reed MG. Unbiased Stereology: Three Dimensional Measurement
in Microscopy. New York, NY: Springer-Verlag; 1998.
31. Korbo L, Andersen BB. The distributions of Purkinje cell perikaryon and nuclear volume in
human and rat cerebellum with the nucleator method. Neuroscience. 1995;69:151-158.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
32. Neter J, Kutner MH, Nachtsheim CJ, Wasserman W. Applied Linear Statistical Models. 4th ed. Chicago, Ill: Irwin; 1996.
33. Littell RC, Milliken GA, Stroup WW, Wolfinger RD. SAS System for Mixed Models. Cary, NC: SAS Institute Inc; 1996.
34. Johnson NL, Kotz S, Balakrishnan N. Continuous Univariate Distributions. New York, NY: Wiley & Sons; 1994.
35. Hayes TL, Lewis DA. Anatomical specialization of the anterior motor speech area: hemispheric
differences in magnopyramidal neurons. Brain Lang. 1995;49:289-308.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
36. Mai JK, Assheuer J, Paxinos G. Atlas of the Human Brain. San Diego, Calif: Academic Press; 1997.
37. Gur RE, Cowell P, Turetsky BI, Gallacher F, Cannon T, Bilker W, Gur RC. A follow-up magnetic resonance imaging study of schizophrenia. Arch Gen Psychiatry. 1998;55:145-152.
FREE FULL TEXT
38. Lieberman JA. Is schizophrenia a neurodegenerative disorder? a clinical and neurobiological
perspective. Biol Psychiatry. 1999;46:729-739.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
39. Fairen A, DeFelipe J, Regidon J. Nonpyramidal neurons, general account. In: Peters A, Jones EG, eds. Cerebral Cortex.
Vol 1. New York, NY: Plenum; 1984:201-245.
40. Woo T-U, Whitehead RE, Melchitzky DS, Lewis DA. A subclass of prefrontal gamma-aminobutyric acid axon terminals are
selectively altered in schizophrenia. Proc Natl Acad Sci U S A. 1998;95:5341-5346.
FREE FULL TEXT
41. Pierri JN, Chaudry AS, Woo T-U, Lewis DA. Alterations in chandelier neuron axon terminals in the prefrontal cortex
of schizophrenic subjects. Am J Psychiatry. 1999;156:1709-1719.
WEB OF SCIENCE
| PUBMED
42. Shelton RC, Karson CN, Doran AR, Pickar D, Bigelow LB, Weinberger DR. Cerebral structural pathology in schizophrenia: evidence for a selective
prefrontal cortical defect. Am J Psychiatry. 1988;145:154-163.
WEB OF SCIENCE
| PUBMED
43. Zipursky RB, Lim KO, Sullivan EV, Brown BW, Pfefferbaum A. Widespread cerebral gray matter volume deficits in schizophrenia. Arch Gen Psychiatry. 1992;49:195-205.
FREE FULL TEXT
44. Andreasen NC, Flashman L, Flaum M, Arndt S, Swayze II V, O'Leary DS, Ehrhardt JC, Yuh WTC. Regional brain abnormalities in schizophrenia measured with magnetic
resonance imaging. JAMA. 1994;272:1763-1769.
FREE FULL TEXT
45. Schlaepfer TE, Harris GJ, Tien AY, Peng LW, Lee S, Federman EB, Chase GA, Barta PE, Pearlson GD. Decreased regional cortical gray matter volume in schizophrenia. Am J Psychiatry. 1994;151:842-848.
WEB OF SCIENCE
| PUBMED
46. Sullivan EV, Lim KO, Mathalon D, Marsh L, Beal DM, Harris D, Hoff AL, Faustman WO, Pfefferbaum A. A profile of cortical gray matter volume deficits characteristic of
schizophrenia. Cereb Cortex. 1998;8:117-124.
FREE FULL TEXT
47. Goldstein JM, Goodman JM, Seidman LJ, Kennedy DN, Makris N, Lee H, Tourville J, Caviness VS, Faraone SV, Tsuang MT. Cortical abnormalities in schizophrenia identified by structural magnetic
resonance imaging. Arch Gen Psychiatry. 1999;56:537-547.
FREE FULL TEXT
48. Bertolino A, Nawroz S, Mattay VS, Barnett AS, Duyn JH, Moonen CTW, Frank JA, Tedeschi G, Weinberger DR. Regionally specific pattern of neurochemical pathology in schizophrenia
as assessed by multislice proton magnetic resonance spectroscopic imaging. Am J Psychiatry. 1996;153:1554-1563.
WEB OF SCIENCE
| PUBMED
49. Bertolino A, Callicott JH, Elman I, Mattay VS, Tedeschi G, Frank JA, Breier A, Weinberger DR. Regionally specific neuronal pathology in untreated patients with schizophrenia:
a proton magnetic resonance spectroscopic imaging study. Biol Psychiatry. 1998;43:641-648.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
50. Buckley PF, Moore C, Long H, Larkin C, Thompson P, Mulvany F, Redmond O, Stack JP, Ennis JT, Waddington JL. 1H-magnetic resonance spectroscopy of the left temporal
and frontal lobes in schizophrenia: clinical, neurodevelopmental, and cognitive
correlates. Biol Psychiatry. 1994;36:792-800.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
51. Deicken RF, Zhou L, Corwin F, Vinogradov S, Weiner MW. Decreased left frontal lobe N-acetylaspartate
in schizophrenia. Am J Psychiatry. 1997;154:688-690.
WEB OF SCIENCE
| PUBMED
52. Moffet JR, Namboodiri MA. Differential distribution of N-acetylaspartylglutamate
and N-acetylaspartate immunoreactivities in rat forebrain. J Neurocytol. 1995;24:409-433.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
53. Bertolino A, Esposito G, Callicot JH, Mattay VS, Van Horn JD, Frank JA, Berman KF, Weinberger DR. Specific relationship between prefrontal neuronal N-acetylaspartate and activation of the working memory cortical network
in schizophrenia. Am J Psychiatry. 2000;157:26-33.
WEB OF SCIENCE
| PUBMED
54. Pakkenberg B. Pronounced reduction of total neuron number in mediodorsal thalamic
nucleus and nucleus accumbens in schizophrenics. Arch Gen Psychiatry. 1990;47:1023-1028.
FREE FULL TEXT
55. Jones L, Mall N, Byne W. Localization of schizophrenia-associated thalamic volume loss. Soc Neurosci Abstr. 1998;24:985.
56. Popken GJ, Bunney WE Jr, Potkin SG, Jones EG. Neuron number and GABAergic and glutamatergic mRNA expression in subdivisions
of the thalamic mediodorsal nucleus of schizophrenics. Soc Neurosci Abstr. 1998;24:991.
57. Young KA, Manaye K, Liang C-L, Hicks PB, German DC. Reduced number of mediodorsal and anterior thalamic neurons in schizophrenia. Biol Psychiatry. 2000;47:944-953.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
58. Wellman CL, Logue SF, Sengelaub DR. Maze learning and morphology of frontal cortex in adult and aged basal
forebrain-lesioned rats. Behav Neurosci. 1995;109:837-850.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
CiteULike Connotea Delicious Digg Facebook Reddit Technorati Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
 |
Cerebral Asymmetry in Schizophrenia
Oertel-Knochel and Linden
Neuroscientist 2011;17:456-467.
ABSTRACT
Postnatal Developmental Trajectories of Neural Circuits in the Primate Prefrontal Cortex: Identifying Sensitive Periods for Vulnerability to Schizophrenia
Hoftman and Lewis
Schizophr Bull 2011;37:493-503.
ABSTRACT
| FULL TEXT
Goal Representations and Motivational Drive in Schizophrenia: The Role of Prefrontal-Striatal Interactions
Barch and Dowd
Schizophr Bull 2010;36:919-934.
ABSTRACT
| FULL TEXT
Mitochondrial Complex I Activity and Oxidative Damage to Mitochondrial Proteins in the Prefrontal Cortex of Patients With Bipolar Disorder
Andreazza et al.
Arch Gen Psychiatry 2010;67:360-368.
ABSTRACT
| FULL TEXT
The Neurodevelopmental Hypothesis of Schizophrenia, Revisited
Fatemi and Folsom
Schizophr Bull 2009;35:528-548.
ABSTRACT
| FULL TEXT
A set of differentially expressed miRNAs, including miR-30a-5p, act as post-transcriptional inhibitors of BDNF in prefrontal cortex
Mellios et al.
Hum Mol Genet 2008;17:3030-3042.
ABSTRACT
| FULL TEXT
GABA Neurons and the Mechanisms of Network Oscillations: Implications for Understanding Cortical Dysfunction in Schizophrenia
Gonzalez-Burgos and Lewis
Schizophr Bull 2008;34:944-961.
ABSTRACT
| FULL TEXT
Progressive and Interrelated Functional and Structural Evidence of Post-Onset Brain Reduction in Schizophrenia
Salisbury et al.
Arch Gen Psychiatry 2007;64:521-529.
ABSTRACT
| FULL TEXT
Anomalies of asymmetry of pyramidal cell density and structure in dorsolateral prefrontal cortex in schizophrenia
CULLEN et al.
Br. J. Psychiatry 2006;188:26-31.
ABSTRACT
| FULL TEXT
Relationship of Brain-Derived Neurotrophic Factor and Its Receptor TrkB to Altered Inhibitory Prefrontal Circuitry in Schizophrenia
Hashimoto et al.
J. Neurosci. 2005;25:372-383.
ABSTRACT
| FULL TEXT
Cell density and cortical thickness in Heschl's gyrus in schizophrenia, major depression and bipolar disorder
Cotter et al.
Br. J. Psychiatry 2004;185:258-259.
ABSTRACT
| FULL TEXT
Human Dysbindin (DTNBP1) Gene Expression in Normal Brain and in Schizophrenic Prefrontal Cortex and Midbrain
Weickert et al.
Arch Gen Psychiatry 2004;61:544-555.
ABSTRACT
| FULL TEXT
Reciprocal Alterations in Pre- and Postsynaptic Inhibitory Markers at Chandelier Cell Inputs to Pyramidal Neurons in Schizophrenia
Volk et al.
Cereb Cortex 2002;12:1063-1070.
ABSTRACT
| FULL TEXT
Altered Spatial Arrangement of Layer V Pyramidal Cells in the Mouse Brain following Prenatal Low-dose X-Irradiation. A Stereological Study using a Novel Three-dimensional Analysis Method to Estimate the Nearest Neighbor Distance Distributions of Cells in Thick Sections
Schmitz et al.
Cereb Cortex 2002;12:954-960.
ABSTRACT
| FULL TEXT
Reduced N-Acetylaspartate in Prefrontal Cortex of Adult Rats with Neonatal Hippocampal Damage
Bertolino et al.
Cereb Cortex 2002;12:983-990.
ABSTRACT
| FULL TEXT
Reduced Neuronal Size and Glial Cell Density in Area 9 of the Dorsolateral Prefrontal Cortex in Subjects with Major Depressive Disorder
Cotter et al.
Cereb Cortex 2002;12:386-394.
ABSTRACT
| FULL TEXT
|